University of Ioannina
Η κυτταρική διαφοροποίηση και η γονιδιακή μεθυλίωση στις αιματολογικές κακοήθειες
Abstract
dc:descriptionBackground: Cell differentiation represents a normaldevelopmental process of all living beings. When a cell acquires its identity it is very improbable that its fate could be reversed even if the cell is situated in another environment. Cell differentiation necessitates no changes in the sequence of DNA and it seems that is under epigenetic control. In order to achieve normal cell differentiation it is necessary that some genes are silenced and not expressed in a cell-specific manner. The epigenetic mechanism that has been best studied is DNA methylation which is associated with gene transcriptional silencing and occurs in cytosines that procceed guanines in genome sequence. The reaction is catalyzed by DNA methyltransferases which attack a methylgroup in the C5 position in the cytosine ring structure. Epigenetic changes represent the first step of cell differentiation. Although epigenetic control establish early during development and cell differentiation, continuous readjustment occurs during cell cycle as response to internal and external stimuli resulting in oncogenesis. Aim: Aim of the study is to observe the methylation pattern of the MEG3 and SNRPN imprinted genes in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and multiple myeloma MM). Moreover, aberrant methylation is correlated with overall survival, disease stage, disease subtypes, cytogenetic abnormalities, and blood counts. Patients and Methods: Bone marrow genomic DNA of 85 newly diagnosed and previously untreated patients with AML (42 patients-49.4%) and MDS (43 patients-50.6%) who presented at the Department of Haematology of the University Hospital of Ioannina were evaluated. There were 57 males (67.1%), and 28 female patients (32.9%) with a mean age 71.8±13.3 years (range 16-92). All individuals were classified according to the WHO classification, and patients with MDS were re-valuated in order to fulfil the diagnostic criteria recently published. The recently proposed WHO classification-based prognostic scoring system for MDS (WPSS) was used for risk stratification of MDS patients. Bone marrow samples were also obtained, from 21 MM patients. Diagnosis of MM was based on previously published criteria. There were 21 patients (11 males-10 females) with median age 66.5 years (range 48-85 years). The MM subtypes were as following: IgG 17 patients (80.96%), IgA 3 patients (14.28%), IgM 1 patient (4.76%). DNA was extracted from bone marrow nucleated cells collected in EDTA containing tubes, and bisulphite treatment was performed using the QIAmp® DNA Mini Kit, (Qiagen), and EZ DNA methylation kit (Zymo Research) respectively according to manufacturers’ instructions. The methylation status of both genes was determined by using conventional methylation specific PCR (MSP). For MSP reaction we used the HotStarTaq Master Mix kit of Qiagen. Results: The normal pattern of MEG3 consists of 2 bands (alleles), namely one corresponding to the methylated paternal allele, (size 160 bp) and one corresponding to the unmethylated maternal allele (size 120 bp). In abnormal methylated samples only the methylated (paternal) allele (160bp) can be observed, while the unmethylated (maternal) allele (120 bp) is not generated. Abnormal methylation pattern of the MEG3 DMR was observed in 35 out of 85 patients (41.2%) evaluated with myeloid malignancies (i.e. MDS and AML patients). In particular, the aberrant methylation was observed in 15 MDS patients (34.9 %) and in 20 individuals (47.6%) with AML. Patients with RAEB-I were 20 fold more likely to present the MEG3 gene abnormally methylated (OR=20, p=0.027). The normal pattern of SNRPN consists of 2 bands, one corresponding to the methylated maternal allele, (size 174 bp) and a further band corresponding to the unmethylated paternal allele (size 100 bp). In the case of DMR aberrant methylation only the methylated (maternal) allele is observed, while the unmethylated (paternal) allele is not. Abnormal methylation was found in 36 patients (42.4%) of the 85 studied. With regard to MDS patients, 15 patients (34.9%) presented only the maternal allele, and twenty one AML individuals (50%) had SNRPN CpG methylation. MEG3’s DMR CpG methylation was associated with significant reduced OS in AML patients (HR=1.98, p=0.047), while SNRPN was not associated with OS (HR=0.94, p=0.87). In MDS, there was a trend in patients with abnormal MEG3 methylation for reduced overall survival (HR=2.15, p=0.072). ...............................................................................................................
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Benetatos, Leonidas
- Μπενετάτος, Λεωνίδας
Subjects
dc:subject × 20- Κυτταρική διαφοροποίηση
- Γονιδιακή μεθυλίωση
- Οξεία μυελογενής λευχαιμία
- Μυελοδυσπλαστικά σύνδρομα (MDS)
- Πολλαπλό μυέλωμα
- Γονίδιο MEG3
- Γονίδιο SNRPN
- Συνολική επιβίωση
- Cell differentiation
- Gene methylation
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Multiple myeloma
- MEG3 gene
- SNRPN gene
- Overall survival ( OS)
- Ιατρική και Επιστήμες Υγείας
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19852